Psilocybin-assisted therapy for persistent post concussion symptoms
About the Study
The Monash-led trial, funded by a $1.5 million Medical Research Future Fund grant, will take place in Melbourne over three years, beginning in 2026.
It is Australia’s first randomised, double-blind, active placebo-controlled clinical trial investigating the efficacy of psilocybin-assisted therapy for persistent post-concussion symptoms in humans.
It will study the effect of the drug on people who have had persistent post-concussion symptoms for at least six months, regardless of the cause of the original concussion.
Find out more and register your interest to participate in the trial: